MD| IM resident| @accintouch IM program| Aspiring 🫀

Georgia, USA
Joined August 2011
👉Oral PCSK9 inhibitors: A new era of intensive LDL-C lowering. ☝️Key takeaways: 1️⃣ Enlicitide: ~60% LDL-C reduction across three Phase 3 trials, with sustained efficacy through 52 weeks. 2️⃣ Laroprovstat: Up to 51% LDL-C reduction in Phase 2, with a distinct mechanism of action and no fasting requirement. 3️⃣ Combination therapy: Oral PCSK9-targeted therapies plus statins could achieve >80% LDL-C reductions with a single daily pill. 4️⃣ The next milestone: CORALreef-Outcomes and AZURE-Outcomes will establish whether these impressive LDL-C reductions translate into cardiovascular benefits. 5️⃣ The real challenge: Efficacy is no longer the main limitation. Access, affordability, clinical adoption, and long-term adherence will determine real-world impact. ☝️ “Ultimately, their success will be measured not only by their efficacy in clinical trials, but by the degree to which they enable more patients with or at risk for ASCVD to reach lipid goals in routine practice.” 🔗 10.1097/MOL.0000000000001061 @society_eas @AnnMarieNavar
5
41
1
144
6,163
✍️Regarding (contraindications and causations) SGLT-2 inh 💫
6
21
1,223
✍️Medications of 🫀HFpEF
1
24
103
4,596
My sincere thanks to @HFSA and the @JCardFail for the opportunity to lead this work, and to an outstanding writing group of colleagues from across the country for their expertise and dedication. Read the full report: onlinejcf.com/article/S1071-… #HFSTATS #HFSA2026
1
21
1
58
2,792
Dolapo retweeted
Replying to @MyJSCAI
Excited to share our study that was recently published in JSCAI, special thanks to @EmiBobManuel2 for the mentorship and special thanks to my awesome co-authors @maxflare @CChinnatambi @wazza_233 @TitaniumMD #cardiology
1
2
5
113
A very proud moment: my new proposed definition of MINOCA with the “I” for “injury” and not “infarction”, has been adopted worldwide by the 5th Definition of Myocardial Infarction Guideline by @escardio, @ACCinTouch, @AHAScience @worldheartfed An important step in making an accurate diagnosis for adequate treatment. new definition of MINOCA academic.oup.com/eurheartj/a…
8
27
4
92
4,204
🫀2026 ESC心不全ガイドライン、ついに公表。 2021年版+2023年アップデートから「かなり」変わりました。まず要点だけ👇 ✅️HFmrEFが消滅。HFrEF=LVEF <50%、HFpEF=LVEF ≥50%の2分類に ✅️MRAとSGLT2阻害薬がLVEF問わずClass I(HFpEFでは非ステロイド性MRAも可‼️) ✅️GDMTをFMT(基盤治療)とAMT(追加治療)に再定義、デバイス/カテーテル治療はGDIT ✅️肥満合併HFにセマグルチド/チルゼパチド(IIa)が初登場 ✅️M-TEERがClass Iに格上げ ✅️心臓リハビリと緩和ケアがClass Iに ✅️ATTR-CMにvutrisiran(silencer)が推奨に追加(Class I A) 詳細はスレッドで🧵 escardio.org/guidelines/clin…
5
835
81
2,508
236,120
#SGLT2i 🫱🏾‍🫲🏽#MRA foundational therapy as class I recommendation for all patients with HF irrespective of LVEF massive workflow implication: implement early after HF syndrome established alongside further LVEF phenotyping! #ESCGuidelines #ESCCongress
1
48
2
155
7,874
Dolapo retweeted
Presented at #ESCCongress: In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results: nej.md/4ii61XB Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke nej.md/45FR7D4 @escardio
3
115
12
327
47,201
🫀Types 1, 2, 3, 4 and 5 myocardial infarction as we knew them are gone. Perhaps the most important conceptual change presented this morning at #ESCCongress comes from the Fifth Universal Definition of Myocardial Infarction. The new classification moves away from numbers and toward pathophysiology. We now have three clinical categories: Primary MI now includes the complete spectrum of acute primary coronary pathology, not only atherothrombosis. Plaque rupture or erosion, spontaneous coronary artery dissection, coronary embolism and coronary vasospasm all belong here. Even restenosis, stent thrombosis or graft failure occurring more than 30 days after a procedure are considered new primary coronary disease rather than late procedural MI. This fundamentally cleans up one of the problems of the old Type 2 classification. And Type 2 MI? The concept becomes secondary myocardial infarction, but importantly with greater diagnostic specificity. An ICU patient with sepsis, anaemia, hypoxaemia, hypotension, tachyarrhythmia or severe hypertension may have a rise and fall in troponin. That establishes acute myocardial injury. It does not automatically establish myocardial infarction. For secondary MI, the injury must occur in the context of oxygen supply–demand imbalance with evidence supporting myocardial ischaemia, and the new document places much greater emphasis on objective coronary or cardiac imaging when appropriate. For those of us working with critically ill patients, this distinction matters enormously. Troponin is a marker of myocardial injury. Ischaemia makes it myocardial infarction. The mechanism tells us which infarction we are dealing with. There are other major changes. Type 3 MI disappears. Sudden cardiac death suspected to be due to MI should instead be classified as primary, secondary or procedure-related according to the clinical setting or post-mortem findings. Types 4 and 5 disappear as separate entities. PCI- and surgery-related events are unified under procedure-related MI, applying a common mechanistic framework to cardiac procedures. And importantly, the old arbitrary troponin thresholds of 5× and 10× the 99th percentile are no longer the basis for defining PCI- and CABG-related MI. The emphasis shifts toward demonstrating a clinically meaningful procedural coronary complication and myocardial consequences. Another fascinating change: MINOCA no longer means “myocardial infarction with non-obstructive coronary arteries”..It is now “myocardial injury with non-obstructive coronary arteries.” A deliberate reminder that MINOCA is a working diagnosis, not an aetiological endpoint. @European Society of Cardiology @escardio #ESCCongress #MyocardialInfarction #Troponin #ACS #CriticalCare #Cardiology @escardio @ACCinTouch @American_Heart @worldheartfed @ehj_ed @KralerSimon @drmilicaa
69
7
205
12,361
🚨 The 2026 @escardio #HeartFailure Guidelines are here❗️#ESCcongress @secardiologia 1) HFmrEF is gone. Acute HF is gone. NT-proBNP cut-offs are now age-adjusted. Everything that matters 🧵👇 2/ 🔄 NEW DEFINITION — two phenotypes only ❤️‍🩹 HFrEF → LVEF <50% + symptoms/signs 🫀 HFpEF → LVEF ≥50% + symptoms/signs + objective evidence of structural/functional abnormality ❌ HFmrEF eliminated: same aetiology, same pathophysiology, same treatment response as HFrEF
7
250
10
568
42,722
NEW 2026 #ESCGuidelines for the management of heart failure 👇ow.ly/km3250ZGoe9 #ESCCongress
5
878
78
1,867
204,094
NEW: Patient version of 2026 #ESCGuidelines on Cardiac Rehabilitation 👉 ow.ly/iNAI50ZGpKl This guide applies to adults who are recommended to receive cardiac rehabilitation at a local centre or in their own home as an outpatient. Please share it with your patients. #ESCCongress #ESCPatientForum
34
1
66
5,798
NEW 2026 #ESCGuidelines - Fifth Universal Definition of Myocardial Infarction (2026) 👇 ow.ly/yn8J50ZGofb #ESCCongress
2
365
30
918
74,150
We are delighted to introduce our amazing #ESCMotions Team at #ESCCongress 👉@rafavidalperez @slumberbell @SMosteoru @corneliacrm @drmilicaa @Massimi78530343   Follow them to get the good vibes and excitement of #ESCCongress!😄📷
9
29
4,994
Tailored Treatment of Myocardial diseases, Endocarditis and Atrial Fibrillation - HOTLINE 1 👇 #ESCCongress
133
2
336
22,310
🚨 Grateful to share that our new paper on DAPT duration after acute coronary syndrome has been published in Cardiovascular Revascularization Medicine! 📈 Across 7 RCTs and 17,515 ACS patients, 3-month DAPT followed by monotherapy performed just as well as 12-month therapy for ischemic protection, while meaningfully reducing bleeding. ✅ Key findings: MACCE: 5.6% vs 5.7% (RR 0.96; 95% CI 0.79–1.17) — no difference Clinically relevant bleeding: 3.0% vs 4.9% (RR 0.62; 95% CI 0.50–0.76) — a 38% relative risk reduction, NNT of 52 Net adverse clinical events: 7.9% vs 9.7% (RR 0.81; 95% CI 0.66–1.00) 💡 Trial sequential analysis found: Conclusive evidence of futility for added ischemic benefit with longer DAPT Conclusive evidence of benefit for bleeding reduction with abbreviated DAPT 🙏 Grateful to Drs. @IbebuoguMD , @DrDrewKleinPHI , @tristonsmithmd , and Sudhir Mungee for their mentorship and guidance throughout this project, and to my co-authors for their contributions! [@louise_orth ,@sahmIbrah]
5
1
5
1,119
The updated 2026 ACC Expert Consensus Decision Pathway for the Management of #HFpEF reflects a significant evolution in how HFpEF is understood and treated. Read the full document in #JACC ➡️ bit.ly/3RVs4sl #CardioX
78
7
147
29,650
💬 Editorial: Exercise testing is safe and helps identify physiological limitations in asymptomatic severe #AorticStenosis, supporting more precise risk assessment and intervention planning. ja.ma/4wkWeEu
9
2
18
2,622
The Lp(a)-lowering drug pipeline is heating up. 💉 Pelacarsen (antisense) — monthly injection, Phase 3, expected FDA approval mid-2027 💉 Olpasiran (siRNA) — quarterly injection, Phase 3, ~2028 💉 Lepodisiran (siRNA) — every 6–12mo injection, Phase 3, ~2029
20
56
2,604